Objectives/Hypothesis: Detection of microscopic disease during surgical resection of melanoma remains a significant challenge. To assess real-time optical imaging for visualization of microscopic cancer, we evaluated three US Food and Drug Administration (FDA)-approved therapeutic monoclonal antibodies.
INTRODUCTION
Although melanoma makes up only 3% of all skin cancers, it accounts for 83% of skin cancer deaths, making it the most lethal form of skin cancer. 1 Head and neck melanoma, in particular, has been shown to be more aggressive and carries an increased mortality rate compared to other locations. 2, 3 Currently, standard of care includes wide local excision with a gross margin of uninvolved surrounding tissue. Significant controversy, however, exists over the recommended width of margins needed for clearance. 4 Immunostaining has been employed for more accurate detection of melanocytic disease, but this requires a significant amount of time and is associated with relatively high costs. 5, 6 Therefore, there is much interest in developing a technique to optimize positive margin detection intraoperatively. A real-time cancer imaging modality has the potential to improve patient outcomes through decreased positive margin rates, sparing of uninvolved tissue, and improved survival overall.
Imaging techniques using the near-infrared (NIR) (700-900 nm) region have emerged as a promising solution to intraoperative cancer detection and resection. Fluorophores, such as IRDye800CW, emitting light in the 800-nm region, have shown better tumor-to-background ratios (TBRs) because of increased depth penetration and lower nonspecific fluorescence. 7 The increased depth penetration of these fluorophores is of particular clinical relevance for melanoma where Breslow's thickness has prognostic implications. Concurrently, novel biomarkers and therapeutic targets for melanoma are emerging. Among them are epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), whose deregulated pathways have been implicated in the sustained proliferation, survival, invasion, and metastases of melanoma cells. 8 Interleukin-6 receptor (IL-6R) has been suggested to be highly involved in melanoma development. 9 Antibodies against these proteins (panitumumab, bevacizumab, and tocilizumab, respectively) have already been developed and approved by the US Food and Drug Administration (FDA). The use of monoclonal antibodies coupled to various fluorophores for imaging purposes have been reported in different tumor types. [10] [11] [12] It is unknown if fluorophore-labeled antibodies can be successfully used to improve margin status in malignant melanoma.
We hypothesize that both macroscopic and microscopic melanoma can be detected by a real-time intraoperative imaging system (SPY System; Novadaq, Toronto, Canada) using monoclonal antibodies conjugated to IRDye800CW. In addition, we sought to determine which fluorescently labeled FDA-approved antibody (bevacizumab, panitumumab, or tocilizumab) had the optimal imaging properties in a preclinical murine model.
MATERIALS AND METHODS

Cell Lines and Tissue Culture
A375 and SKMEL5 (ATCC, Manassas, VA) were the melanoma cell lines used. Tumor heterogeneity has become a challenge to development of targeted therapeutics or imaging agents and for tumor characterization. Therefore, we experimented with two different melanoma cell lines to validate the methodology and technology. Cells were grown and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 1% penicillin, streptomycin, and amphotericin B. Cells were incubated at 37 C in 5% CO 2 . A total of 2 3 10 6 cells in 200 lL of phosphate buffer solution (PBS) were administered subcutaneously.
Reagents
Antibodies included bevacizumab (Avastin; Genentech, San Francisco, CA; 149 kDa), panitumumab (Vectibix; Amgen, Thousand Oaks, CA; 147 kDa), and tocilizumab (Actemra; Genentech; 148 kDa) (Table I ). Control antibody was protein A purified immunoglobin G (IgG) antibody (Innovative Research, Inc., Novi, MI; Ir-Hu-Gf, #30010BM; 146kDa). Immunohistochemical analysis with HMB-45 (Human Melanoma Black, antimelanoma antibody; mouse monoclonal, catalog #ab787; Abcam, Cambridge, MA) was performed to confirm melanoma tumor cells. HMB-45 was chosen for its high specificity, although other immunohistochemical stains for melanoma are available. Staining was performed as previously described.
13 IRDye800CW (IRDye800CW-N-hydroxysuccinimide ester; LI-COR Biosciences, Lincoln, NE), with an absorption and emission peak of 778 nm/ 794 nm, was the fluorescent probe. Maximums decrease slightly (774 nm/789 nm) when conjugated to an antibody.
14 Bevacizumab, panitumumab, tocilizumab, and IgG were labeled according to the manufacturers' protocol. This involved incubation with the IRDye800CW for 2 hours and removal of unconjugated dye by desalting columns (Pierce, Zeba, #89891).
Binding Affinity Assay
Binding affinity assays for each antibody were performed to determine if antigen specificities were retained after fluorescent labeling with IRDye800CW. Six lanes of a 96-well black plate were coated with recombinant EGFR (rEGFR/ErbB1; 400 ng/well/100 lL; Fc Chimera, 344-ER), IL-6R (rIL-6Ra; 400 ng/well/100 lL; 227-SR/CF), or VEGF (rVEGF; 100 ng/well/ 100 lL; 293-VE/CF) overnight at 4 C. Wells were blocked for 1 hour at room temperature with 1% bovine serum albumin, then washed with PBS three times. For control, purified antibody was added to three lanes of coated wells and allowed to block for 1 hour. Serial dilutions of labeled antibody (0.234375-30 nM for bevacizumab and tocilizumab; 0.05-6.7 nM for panitumumab) were then added to all coated wells and incubated for 1 hour. Uncoated wells on the same plate were also maintained for background control. After incubation, wells were washed with PBS and imaged using the Pearl Impulse imager (LI-COR Biosciences). Well intensities were quantified using the Pearl Impulse software version 2.0.
Animal Models
Nude (nu/nu) and severe combined immunodeficient female mice (Charles River Laboratories, Hartford, CT), aged 4 to 6 weeks, were housed in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines. All experiments were conducted and mice euthanized according to IACUC guidelines. monitored weekly until they reached 25 mm 2 . The flank model was chosen for the initial site in the first four mice to evaluate if the antibody-dye conjugates would localize and fluoresce, and if so, compare them to nonspecific IgG-IRDye800CW. Tail vein injections were administered with one of the three fluorescently labeled antibodies or IgG (200 lg). For the human split-thickness skin grafts (STSG), samples were obtained by informed consent for patients undergoing head and neck cancer surgery. Tissue samples approximately 2 3 2 cm in size were transported on ice from the operating room to the lab. Skin from the back of a nude mouse was then excised. The skin graft was then sutured into place and monitored for satisfactory uptake. Once graft survival was ensured, each mouse was systemically injected with one of the labeled antibodies. As previously demonstrated, this was done to determine the expected background fluorescence in humans. 13, 15, 16 In the ear model, three mice were injected on the dorsal side of the ear with A375 cells. Tumor size was monitored, and tail vein injections were performed with one of the three labeled antibodies. Mice were then imaged by SPY and Pearl for 21 days to assess peak fluorescence and stability of each labeled antibody over time. Because the Pearl adjusts the range of fluorescence to optimize the image, ranges were standardized (0.00E 0 to 24.34E
21
) for all mice over 21 days for objective comparison. Fluorescence intensity was quantified using ImageJ software (National Institutes of Health, Bethesda, MD). 17 Several regions of interest within the tumor were selected using an equal-sized circle, and a mean value was calculated. The same technique was used to measure background (defined as adjacent normal tissue within 1 cm of tumor) fluorescence intensity. TBRs were then calculated.
Finally, the ear model was used for the surgical resections as it allows for both lymphatic and hematogenous spread and has been shown to accurately represent metastatic melanoma. 18 Eighteen mice received injections of the appropriate cell line on the dorsal ear. Mice were then injected with one of the three labeled antibodies, three mice per antibody in each cell line. TBRs were calculated.
Fluorescent Imaging and Measurement
The sequence of real-time fluorescent-guided resection and positive specimen confirmation by a second fluorescent imager is illustrated in Figure 1 . The SPY imaging system captures fluorescent light using a charged couple device video camera at a rate of 30 frames/second, allowing the user to visualize images in real time on a computer monitor. 19 This system was used to guide tumor resections 48 hours following antibody-dye conjugate injections. Mice were also imaged with the Pearl. Additional imaging allowed for colocalization and verification of fluorescence seen by the SPY. Following resections, excised tissues were placed in tissue cassettes and imaged with both modalities.
Microscopic Fluorescent Imaging
Images were obtained by fluorescence microscopy using an Olympus IX81 Inverted Microscope (Olympus, Hamburg, Germany) (equipped with a halogen bulb and NIR filter cube (EXHQ760/40X, 790 dcxr, EMHQ830/50m; Chroma Technology Corp., Rockingham, VT).
Statistical Analysis
For each cell line, TBRs of each antibody were compared using a one-way analysis of variance (ANOVA) test with a Tukey's post-test using GraphPad Prism version 5.04 for Windows (GraphPad Software, San Diego, CA). Statistical analysis was performed by the lead author and significance was considered P < .05.
RESULTS
Specificity of Bevacizumab, Panitumumab, and Tocilizumab for Imaging Melanoma
To determine the corresponding antigen expression for each antibody in our model, protein analysis of melanoma cell line tumors grown in vivo and normal skin samples was assessed by Western blotting for the proteins of interest (Supplemental Fig. 1) . EGFR, VEGF, and IL-6R, demonstrated strong expression in the A375 and SKMEL5 cell line tumors grown in vivo. We then evaluated whether our fluorophore-labeled antibodies retained antigen specificity in vitro using an optical Scatchard analysis (data not shown). Each antibody maintained antigen specificity after IRDye800CW labeling. The binding affinity of labeled antibody was assessed at eight different concentrations and was found to approach that of the unconjugated antibody (Supplemental Fig. 2) .
NIR Fluorescent Imaging of Tumors
In vivo specificities were evaluated by comparing uptake of fluorescently labeled antibodies to the uptake of nonspecific IgG-IRDye800CW in mice with A375 flank tumors. Tumor fluorescence was evaluated and compared using both SPY and Pearl. As we have shown in other tumor types, 13, 15, 16 labeled IgG does not achieve notable contrast, and this was again true in melanoma tumors. These data imply that better tumor specificity exists with fluorescently labeled antibodies.
To determine expected background fluorescence in humans, the uptake of each antibody-dye conjugate was evaluated in human STSGs. The human STSGs showed comparable background fluorescence to mouse skin (data not shown). This suggested that all three labeled antibodies would exhibit TBRs sufficient to guide surgical resections in humans.
Three mice with A375 tumors were imaged daily for 21 days to assess peak fluorescence of each fluorescently labeled antibody as well as stability over time. Figure 2 illustrates the fluorescence intensities achieved. Intensity ranges were standardized for fair comparison on the Pearl imager; therefore, tumor fluorescence saturation occurs during the first few days and normalizes over time. Panitumumab achieved the highest TBRs with both SPY and Pearl (3.8 and 6.6) on days 8 and 20, respectively. Next was bevacizumab, with TBRs of 3 and 5.8 on SPY and Pearl, whereas tocilizumab only attained TBRs of 2.9 and 5.1. SPY's fluorescent peaks occurred between days 5 and 9 for the three antibodies, whereas they occurred much later (between days 15 and 20) using the Pearl. By day 21, panitumumab still had enough contrast to produce TBRs of 2.5 and 6.5 (SPY, Pearl). Bevacizumab and tocilizumab were lower at day 21 (1.9 and 4.9; 1.4 and 3.4). These data suggested that panitumumab would perform best over time.
In the ear model, all fluorescently labeled antibodies achieved sufficient contrast to guide surgical resection (Fig. 3A) . In comparing antibodies against each other, however, we found no significant difference with either imaging modality or cell line (A375: P 5.27 SPY, P 5.72 Pearl; SKMEL5: P 5.41 SPY, P 5.08 Pearl; oneway ANOVA). On further analysis, a Tukey's post-test also did not reveal any differences among antibodies. Therefore, all three antibodies produced appreciable TBRs in the ear model, signifying clear differentiation from healthy background tissue.
Specific values for each antibody in each cell line are as follows: In the A375 cell line tumors (n 5 9), tocilizumab achieved the highest TBR of 1.6 using the SPY, whereas bevacizumab achieved a TBR of 3.4 with the Pearl. TBR ranges for SPY and Pearl were 1.4 to 1.6 and 2.4 to 3.4, respectively. In the SKMEL5 tumors (n 5 9), the findings were similar. Tocilizumab attained the best TBR (1.9) using the SPY, and bevacizumab was best with the Pearl (3.0). SPY and Pearl ranges for tumors were 1.6 to 1.9 and 2.3 to 3, respectively (Fig. 3B) .
Resection Using NIR Fluorescence-Guided Imaging
For each mouse, initial tumor imaging using both modalities was performed prior to any resection. Next, the primary tumor was resected in real time under the guidance of the SPY. SPY imaging for the primary tumor resection was then compared to images obtained with the Pearl imager. The wound bed was then reimaged by both modalities for residual fluorescent areas, and the SPY was again used in the real-time resection of these fluorescently positive areas. As demonstrated in Figure  4A , fluorescently labeled bevacizumab and panitumumab were able to identify residual disease (0.5 3 0.4 cm and 0.6 3 0.6 cm, respectively) after primary tumor resections. Under white light, it was unclear if these areas were tumors or not. The SPY and Pearl revealed fluorescence in these areas, and residual tissue samples were later confirmed for the presence of melanoma by pathologic examination and HMB-45 staining. With tocilizumab, an axillary lymph node fluoresced and was presumed to be positive for metastasis at the time of resection. As shown in Figure 4B , the primary tumor There was no significant difference with the SPY imaging system. Bevacizumab performed best with the Pearl, but this result was also not significant (B).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
was removed in two pieces and placed in a tissue cassette, whereas a remaining fluorescent area in the axilla was detected by both modalities. This lymph node, however, proved to be negative for melanoma. After tissue processing, positive tumor slides were imaged with an NIR filter-fitted microscope to ascertain dye localization within the tumor (Fig. 5) . Images of negative control tissues confirmed specific antibody-dye localization in tumor tissue. Labeled panitumumab appears to collect in the capillary vasculature of the tumor, whereas bevacizumab and tocilizumab show a more diffuse distribution pattern with areas of intense accumulation throughout. The perivascular binding of panitumumab could represent either EGFR on endothelial cells or on tumor cells surrounding the capillaries. Our images show the labeled antibodies specifically binding tumor parenchyma as opposed to the periphery, 20 and that mechanistically helps to understand where the antibody is binding.
DISCUSSION
Identification of microscopic disease in the operating room remains a critical need to improve surgical outcomes. A melanoma-specific optical contrast agent has the potential to fulfill this need by guiding surgical resections in real time. Here we present data on three fluorophore-labeled antibodies for tumor targeting. Although one did not prove to be significantly better than the other, all achieved higher TBRs and better contrast compared to labeled nonspecific IgG antibody. Furthermore, tumors but not normal human xenografted epithelium showed intense fluorescence. In two cases, bevacizumab and panitumumab were able to identify residual disease and provided improved tumor resections based on pathological evidence. Fluorescence intensities of these two antibodies also proved robust for weeks in serial imaging studies. Conversely, tocilizumab proved to be less specific, and its fluorescence intensity was consistently weaker than the others.
Recently, considerable research has emerged on the development of cancer-specific optical contrast agents that could be used in the operating room to guide surgical resections. 21 Fluorescent imaging of melanoma has concentrated on sentinel lymph node mapping versus primary lesions. [22] [23] [24] [25] [26] Because of its locally aggressive nature, however, primary tumor resections cannot be ignored. Optical imaging holds great promise in improving primary tumor resections and could significantly impact melanoma patient outcomes. Tumor targeting, however, is a particular challenge in melanoma, where no consistent biomarker has yet emerged. In prostate cancer, for example, prostate-specific membrane antigen is abundantly expressed on both the surface and within prostate tumors. This presents itself as an ideal tumortargeting ligand and has shown promise in fluorescent imaging studies. 27, 28 Because no such marker exists for melanoma, and given our previous successes with conjugated antibodies, 10, 11, 13 we evaluated the use of FDAapproved antibodies in fluorescent-guided resections of primary melanoma tumors. Because of their established pharmacokinetics and safety in humans, antibodies carry a greatly reduced risk for clinical translation. They also confer the advantage of a longer half-life, which allows for better accumulation within tumors over days. In fact, high sensitivity in optical imaging is related to the probe's ability to accumulate and be retained in a targeted area. 29 Antibodies, therefore, present themselves as a promising tumor-targeting technique.
Imaging in the near infrared spectral range (700-900 nm) also imparts particular advantages for melanoma. Not only does this range decrease autofluorescence by decreasing interference from solvents and biomolecules, but it also allows for further penetration into the tissues. 29 This is of extreme importance in melanoma, where depth of invasion has prognostic implications. Unfortunately, few approved NIR fluorescent agents specifically designed for conjugation to targeting molecules exist. Cy5.5 and IRDye800CW are two such agents being investigated for clinical applications of optical imaging. IRDye800CW has demonstrated better tissue penetration and produces improved TBRs compared to Cy5.5. 30 Furthermore, IRDye800CW has an absorption and emission peak very similar to that of indocyanine green (ICG), a dye commonly used by plastic surgeons for intraoperative angiography. The SPY imaging system used in this study is one such device designed for that purpose and is available at many tertiary care institutions (either as purchase or lease). 31 By using this imaging technology, our approach differs from many other groups. 7, 32 The use of preexisting technology facilitates cost-effective implementation in operating rooms because investment in additional equipment is not required. Co-opting existing antibody targeting technology also differs from other approaches by leveraging current FDA approvals and safety information.
Although the labeled antibodies proved successful at delineating tumor from healthy tissue and EGFR, VEGF, and IL-6R were overexpressed in Western blot analysis of tumor tissue, it should be noted that they are not melanoma specific. This was particularly noticeable when imaging with tocilizumab. Because IL-6 is a multifunctional cytokine that regulates immune responses and acute phase reactions, 33 its receptor may not be a very specific tumor marker. Another limitation may have been the circumscribed nature of the mouse tumors. Although nodular subtypes of melanoma do exist, this tumor quality did not simulate the often infiltrative nature of melanoma seen in humans. Finally, our chosen fluorophore of IRDye800CW is not currently approved for human use and poses a barrier to clinical translation. The only approved NIR fluorophore in the United States for humans (ICG) is unfortunately unable to label targeting agents. However, a promising study by Marshall et al. has demonstrated no toxic or adverse effects of IRDye800CW in rats in doses up to 20 mg/kg. 34 
CONCLUSION
Our data show antibodies to be an effective tumor targeting strategy in NIR real-time fluorescent imaging of melanoma. Benefits of this strategy include the utilization of FDA-approved agents with better accumulation in tumors and use of current intraoperative hardware. This research merits continued investigations.
